PTX Target Price Revision: Target Upped to A$0.20 – H.C Wainwright & Co
We maintain our Buy rating and are increasing our price target to A$0.20 from A$0.16...
We maintain our Buy rating and are increasing our price target to A$0.20 from A$0.16...
We maintain our Buy rating and are increasing our price target to A$0.16from A$0.09. The...

This investor centre was built by Reach Markets
©2025 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.